Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

433.45 +11.13 (+2.64%)

Streaming Delayed Price Updated: 11:46 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

68 69 Next >

Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment ↗

December 13, 2023

The company tested an alternative to opioids and NSAIDs in patients with diabetic peripheral neuropathy.

Via Investor's Business Daily

Next Wave Biotech: 3 Stocks Poised for Breakthrough Success ↗

December 13, 2023

The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks.

Via InvestorPlace

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading

December 13, 2023

Via Investor Brand Network

1 Biotech Stock That Could Be the Next Amgen ↗

December 13, 2023

The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.

Via The Motley Fool

Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative ↗

December 13, 2023

Vertex stock spiked early Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.

Via Investor's Business Daily

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? ↗

December 13, 2023

Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.

Via The Motley Fool

The Latest Analyst Ratings for Vertex Pharmaceuticals ↗

December 11, 2023

Via Benzinga

Forget the "Magnificent Seven": Buy This Stock Instead ↗

December 09, 2023

It's hard to go wrong with this high-flying drugmaker.

Via The Motley Fool

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

December 13, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine ↗

December 12, 2023

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology.

Via Investor's Business Daily

Biotech Is Coming Back, Can The Run Last? ↗

December 11, 2023

The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.

Via Talk Markets

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Why CRISPR Stock Keeps Falling ↗

December 11, 2023

CRISPR just scored its first FDA victory -- but profits remain years away.

Via The Motley Fool

Bull Of The Day: Crispr Therapeutics ↗

December 11, 2023

CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...

Via Talk Markets

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗

December 11, 2023

A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.

Via The Motley Fool

3 Unstoppable Stocks to Buy Right Now ↗

December 10, 2023

These stocks could be just the ticket for investors seeking strong growth.

Via The Motley Fool

Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? ↗

December 10, 2023

The big biotech's shares have been on the rise this year.

Via The Motley Fool

2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years ↗

December 09, 2023

These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.

Via The Motley Fool

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗

December 08, 2023

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y

Via Benzinga

Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review ↗

December 08, 2023

Treasury yields and crude oil came off multimonth lows on Friday's jobs report.

Via Investor's Business Daily

Topics Artificial Intelligence

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

December 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment ↗

December 08, 2023

Crispr stock rose in early trades on Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment.

Via Investor's Business Daily

CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗

December 08, 2023

The timing of the cuts is setting off alarm bells, but the situation is under control.

Via The Motley Fool

Healthcare Gems: 3 Essential Long-Term Stock Picks ↗

December 07, 2023

Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks.

Via InvestorPlace

This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics ↗

December 07, 2023

Shareholders will do well to prepare themselves for how regulators might react.

Via The Motley Fool

5 Unstoppable Trends to Invest $1,000 in for 2024 ↗

December 07, 2023

These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.

Via The Motley Fool

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

Vertex Appoints Nancy Thornberry to its Board of Directors

December 05, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

December 05, 2023

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.